Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings. The company is dedicated to advancing new standards in neuromodulator products for medical aesthetics and therapeutic applications. Revance's portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, a Relational Commerce platform for aesthetics practices.
The Nashville headquarters serves as the primary center for Revance's executive leadership, strategic planning, corporate operations, commercial activities, and investor relations.
Located in a modern office building in Nashville's Gulch district, the headquarters offers contemporary workspaces designed to foster collaboration, innovation, and employee well-being.
Revance fosters a work culture centered on innovation, scientific excellence, and a commitment to patients and customers. The environment is dynamic, encouraging cross-functional collaboration and agile decision-making to drive growth in the competitive biotech landscape.
The relocation to Nashville strategically positions Revance within a key U.S. healthcare ecosystem, providing access to a rich talent pool, fostering potential partnerships, and supporting its commercial expansion efforts.
Revance Therapeutics primarily focuses its commercial operations on the United States market for its flagship products like DAXXIFY® and the RHA® Collection of dermal fillers. While direct international commercial operations are not extensive, the company sources its RHA® Collection through an exclusive U.S. distribution agreement with TEOXANE SA (Switzerland). Future global expansion for its proprietary products may be pursued through strategic partnerships or phased market entries.
1222 Demonbreun Street, Suite 2000
Nashville
TN
USA
Address: 7555 Gateway Boulevard, Newark, CA 94560
Located in the San Francisco Bay Area, this office leverages the region's dense concentration of biotech talent, research institutions, and venture capital, crucial for continued innovation and development.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Revance' leadership includes:
Revance has been backed by several prominent investors over the years, including:
Revance Therapeutics has actively shaped its executive team over the past year, making key appointments to bolster its commercial, R&D, medical, and people operations capabilities. Notable additions include a new Chief People Officer, Head of Research and Development, and Chief Medical Officer. There was also a significant transition involving the former head of R&D and Product Operations moving into a consultancy role which later concluded.
Discover the tools Revance uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Revance Therapeutics generally utilizes common corporate email formats. The most frequently observed pattern is a combination of the employee's first initial and last name, or first name and last name separated by a period, followed by '@revance.com'.
Common formats include [first_initial][last]@revance.com (e.g., jdoe@revance.com) and [first].[last]@revance.com (e.g., jane.doe@revance.com).
Format
jdoe@revance.com
Example
75%
Success rate
Revance Therapeutics / Business Wire • May 7, 2024
Revance announced its financial results for Q1 2024, highlighting revenue growth driven by DAXXIFY® and the RHA® Collection of fillers. The company also provided updates on its commercial strategy and product pipeline advancements....more
Revance Therapeutics / Business Wire • May 1, 2024
Revance announced the appointment of David A. Hollander, M.D., M.B.A., as its new Chief Medical Officer. Dr. Hollander will oversee medical affairs, clinical development, and pharmacovigilance....more
Revance Therapeutics / Business Wire • April 16, 2024
Revance presented encouraging long-term efficacy and safety data from its ASPEN-1 OLE Phase 3 study of DAXXIFY® for treating cervical dystonia at the American Academy of Neurology (AAN) Annual Meeting....more
Revance Therapeutics / Business Wire • February 28, 2024
Revance reported its Q4 and full-year 2023 financial results, emphasizing the growth of DAXXIFY® and the RHA® Collection, and outlined its strategic priorities for 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Revance, are just a search away.